Apsen Farmaceutica S.a.

This Phase 3 trial tests a new topical drug called APSMNF for male pattern baldness. About 336 men aged 18 to 60 will apply it twice daily for 24 weeks. Researchers will measure changes in hair density using a special camera and track any side effects.

This Phase II trial tests a new drug called APSTZD for people with chronic insomnia. About 222 adults aged 18-64 will receive either APSTZD, an active comparator (Stilnox CR), or a placebo. The main goal is to see if APSTZD reduces time awake after falling asleep, measured by ove…